Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3.
A state-of-the-art, next-generation automated drug dispensing machine equipped with a robotic arm, independently developed by JVM, an affiliate of Hanmi Science, was successfully launched in the European market.
Alimentiv Inc. ("Alimentiv"), a leading Contract Research Organization focused on GI-related therapeutics, is pleased to announce the addition of new scientific advisors to its scientific advisory board.
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen's innovative CAR-GPC3 T-cell therapy.
Cambrex announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.
Maryland-based biotech company Deka Biosciences ("Deka") announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm.
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that "LEQEMBI® Intravenous Infusion" (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). The regulatory approval in Japan announced today, entitles BioArctic to a milestone of EUR 17 M.
Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of our new CRYOcheck™ Factor VIII Deficient Plasma with VWF in the U.S.
Neoss Group, a leading innovator in dental implant solutions, is proud to announce the fast and easy-to-use wireless intraoral scanner, NeoScan™ 2000. This follows the success of last year's launch of the NeoScan™ 1000.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications.